Valuation: Alumis Inc.

Market Cap 3.23B 2.8B 2.62B 2.39B 4.51B 309B 4.58B 30.77B 12.06B 154B 12.14B 11.88B 515B P/E 2026 *
-8.87x
P/E 2027 * -9.28x
Enterprise Value 2.7B 2.34B 2.19B 2B 3.76B 258B 3.82B 25.68B 10.06B 129B 10.14B 9.92B 430B EV / Sales 2026 *
390x
EV / Sales 2027 * 120x
Free-Float
96.28%
Yield 2026 *
-
Yield 2027 * -
1 day+0.12%
1 week-6.03%
Current month-9.79%
1 month-9.31%
3 months+8.40%
6 months-4.91%
Current year+161.12%
1 week 23.8
Extreme 23.8
28.56
1 month 23.8
Extreme 23.8
30.11
Current year 7.85
Extreme 7.85
31.35
1 year 3.76
Extreme 3.76
31.35
3 years 2.76
Extreme 2.7601
31.35
5 years 2.76
Extreme 2.7601
31.35
10 years 2.76
Extreme 2.7601
31.35
Manager TitleAgeSince
Chief Executive Officer 61 23/09/2021
Director of Finance/CFO 60 01/05/2022
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Director/Board Member 63 01/05/2021
Director/Board Member 60 01/06/2021
Chairman 61 23/09/2021
Date Insider Type Main position Quantity % Market Cap.
03/08/26 Sell

Chief Technology Officer

-2,447 0.0020%
03/08/26 Sell

Executive/Senior Manager

-2,692 0.0022%
03/08/26 Sell

General Counsel

-1,364 0.0011%
Change 5-day change 1-year change 3-year change Capi.($)
-0.10%-6.03%+471.41% - 3.23B
-0.70%+13.34%+75.61%+103.83% 70.51B
+0.91%+0.99%+36.86%+65.39% 54.05B
+1.69%+36.25%+10.59%+505.00% 28.95B
-0.61%+12.51%+54.60%+7.40% 24.05B
-0.16%+1.08%-16.05%-13.27% 23.31B
+9.77%+20.16%+260.17%+472.38% 18.67B
+1.58%+6.82%+46.03%-20.28% 18.37B
0.00%+7.46%+30.95%+623.97% 16.1B
-0.23%-9.92%+34.58%+137.45% 12.72B
Average +1.26%+7.14%+100.47%+209.10% 27B
Weighted average by Cap. +0.91%+9.02%+61.99%+170.90%

Financials

2026 *2027 *
Net sales 6.93M 6M 5.62M 5.13M 9.65M 661M 9.81M 65.9M 25.82M 331M 26.01M 25.44M 1.1B 23.83M 20.66M 19.34M 17.64M 33.2M 2.27B 33.76M 227M 88.83M 1.14B 89.49M 87.54M 3.8B
Net income -375M -325M -304M -277M -522M -35.75B -531M -3.57B -1.4B -17.89B -1.41B -1.38B -59.7B -397M -344M -322M -294M -553M -37.84B -562M -3.77B -1.48B -18.94B -1.49B -1.46B -63.19B
Net Debt -534M -463M -434M -396M -744M -50.97B -757M -5.08B -1.99B -25.51B -2.01B -1.96B -85.12B -371M -321M -301M -274M -516M -35.36B -525M -3.53B -1.38B -17.7B -1.39B -1.36B -59.05B
Logo Alumis Inc.
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of envudeucitinib for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
Employees
226
Date Price Change Volume
12/08/26 $25.42 +0.20% 88,325
11/08/26 $25.37 -7.85% 1,324,326
10/08/26 $27.53 -0.25% 458,965
07/08/26 $27.60 -0.72% 843,458
06/08/26 $27.80 +2.51% 653,457
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
25.37USD
Average target price
40.33USD
Spread / Average Target
+58.98%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALMS Stock